iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 753 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Tobacco-Related Deaths Claim Almost 60,000 Women’s Lives Each Year, And Are... February 18, 2021 Sound Waves Can Target Lymph Nodes And Help Kill Breast Cancer... November 22, 2019 Hundreds Of Thousands Of Peruvian Women Were Forcibly Sterilized, And Now... October 29, 2021 Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable... January 15, 2025 Load more HOT NEWS Addressing Cancer Pain with Complementary Methods (Part 1) Cancer in My Community: The Roadblocks to Receiving Cancer Care in... EMA Recommends Extension of Indications for Crizotinib EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab
